In 2023, CARsgen Therapeutics Holdings completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).
However, CARsgen Therapeutics Holdings has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
In 2023, the total operational greenhouse gas (GHG) emissions of CARsgen Therapeutics Holdings amounted to 15,327.77 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of CARsgen Therapeutics Holdings decreased by 10.78%, showing that the company has made progress in taking action to reduce the climate impact of its operations.
In 2023, the total Scope 1 emissions of CARsgen Therapeutics Holdings were 3,639.12 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Since 2021, CARsgen Therapeutics Holdings's Scope 1 emissions have increased by 3,007.7%, reflecting a rising long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), CARsgen Therapeutics Holdings's Scope 1 emissions decreased by 27.68%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.
In 2023, CARsgen Therapeutics Holdings reported Scope 2 greenhouse gas (GHG) emissions of 11,688.65 tCOâ‚‚e without specifying the calculation method.
Since 2021, CARsgen Therapeutics Holdings's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 26.11%, reflecting a rising long-term trend in Scope 2 emissions over time.
Compared to the previous year (2022), CARsgen Therapeutics Holdings's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that CARsgen Therapeutics Holdings 's emissions have plateaued with no significant change in its energy consumption footprint.
In 2023, CARsgen Therapeutics Holdings reported its Scope 2 emissions using an unspecified methodology.